Last reviewed · How we verify
TFV and FTC Combined Vaginal Tablet
At a glance
| Generic name | TFV and FTC Combined Vaginal Tablet |
|---|---|
| Sponsor | CONRAD |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Safety and Effectiveness of TFV 1% Gel, TDF Tablets, and FTC/TDF Tablets in Preventing HIV in Women (PHASE2)
- Exploratory Pharmacodynamic Study of Tenofovir-Based Products (PHASE1)
- Safety, Pharmacokinetics, Pharmacodynamics, and Disintegration Time of Vaginal Tablets Containing Tenofovir and/or Emtricitabine (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TFV and FTC Combined Vaginal Tablet CI brief — competitive landscape report
- TFV and FTC Combined Vaginal Tablet updates RSS · CI watch RSS
- CONRAD portfolio CI